Sun Pharma Advanced Research Company Ltd.
Snapshot View

260.45 -5.45 ▼-2.1%

26 July 2021, 04:02:12 P.M.
Volume: 3,306,726

Overview View Details

Sector Miscellaneous Compare with Sector peers
Industry Miscellaneous Compare with Industry peers
Website http://www.sparc.life
Financial Indicators
Market Cap 6,839.44 Cr.
Earnings per share (EPS) -5.77 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2021-03
Industry PE 101.18 Trailing Twelve Months Ending 2021-03
Book Value / Share -6.48 Trailing Twelve Months Ending 2021-03
Price to Book Value -40.28 Calculated using Price: 261.00
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 26.20 Cr. 262,047,506 Shares
FaceValue 1
Company Profile

Sun Pharma Advanced Research Company (SPARC) is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery. SPARC was formed in 2007 through a demerger from SUN PHARMA, a global leader in speciality generics. It strive to build an enduring innovation engine built on strong scientific execution, high value analytics and aggressive portfolio management. A robust mix of internal ideation and strategic partnering with academic innovators and bio-pharma entrepreneurs fuel engine with potentially high impact ideas.

The company partner with thought-leading clinicians across the world for ideas and access. Innovation through integration of partner knowledge and efficient internal execution shapes future. SPARC is a vibrant innovation community spread over three locations globally. It endeavour to develop a meritocracy which takes pride in continuous learning and re-invention. SPARC is a responsible public company committed to maintaining highest standards of ethics and transparency.

Business area of the company

The company is engaged in the pharmaceutical research and development. The company’s core focus is innovation and new product development for global markets. SPARC undertakes projects in research and technology for new chemical entities (NCE’s) or new molecules, and novel drug delivery systems (NDDS).

Products

  • Therapeutic Focus (Oncology, Neuro Degeneration, Ophthalmology, Dermatology)
  • Delivery Technologies (Gastro Retentive Innovative Device, Wrap Matrix, Abuse Deterrent Program, Nanotecton Technology, Dry Powder Inhalation, TearAct, Lipixelle, Gel Free Reservoir)
  • Research Programs (Taclantis, SCO - 088, SCD - 044, SCC - 138, SCO - 120)

Milestones

  • 2006: SPARC is founded in Vadodara, India
  • 2007: Innovative R&D business was demerged from Sun Pharmaceutical Industries Limited to focus on innovative drug research
  • 2007: Listed on Bombay Stock Exchange and National Stock Exchange of India
  • 2012: 1st NDA filed with USFDA for Elepsia XR
  • 2012: Raised Rs. 200 crore through Rights Issue
  • 2013: Filed NDA for Xelpros with USFDA
  • 2014: US rights for Xelpros licensed to a subsidiary of Sun Pharma
  • 2015: Entered into research collaboration in the field of Oncology with US University
  • 2015: Launched Bevetex (PICS) in India
  • 2016: Raised Rs. 250 crore through Rights Issue
  • 2017: Secured funding of up to Rs. 500 crore through Preferential Allotment of warrants convertible into equity shares
  • 2018: Entered into collaboration with Schrödinger to accelerate Neurodegeneration Drug Development Programs
  • 2018: Positive top line results reported for the pivotal bioequivalence study of Taclantis (Paclitaxel Injection Concentrate for Suspension)
  • 2018: US FDA approved Xelpros for the treatment of open-angle glaucoma or ocular hypertension
  • 2019: Entered into licensing agreement with Bioprojet SCR to acquire exclusive rights for Investigational Medicinal Product, SCD-044
  • 2019: Entered into a licensing deal with China Medical System Holdings Limited (CMS) to develop and commercialize multiple products in Mainland China, Hong Kong, Macao, and Taiwan
  • 2019: Orphan Drug Designation received from the US FDA for SPARCs neonatal seizures drug, Phenobarbital
  • 2019: Orphan Drug Designation received from the US FDA for SPARCs Chronic Myeloid Leukemia drug, SCO-088
  • 2019: NDA for Taclantis (Paclitaxel Injection Concentrate for Suspension) accepted by US FDA for review
  • 2019: Entered into collaboration with HitGen for Innovative Drug Discovery Research
  • 2020: Entered into a worldwide license agreement for SCD-044 with Sun Pharma
  • 2020: Entered into collaboration with the University of Michigan to kickstart research and development of potential new medications

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-2.05%
1 Week
+6.18%
1 Month
+13.44%
3 Month
+52.31%
6 Month
+41.43%
1 Year
+49.34%
2 Year
+57.80%
5 Year
-27.15%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) -110.94 24.62 -33.17 -109.16 -127.40 -156.84 -74.72 -225.08
Return on Capital Employed (%) -1,066.48 -19.55 24.02 -31.74 -71.37 -94.66 -113.05 -59.95 -178.22
Return on Assets (%) -88.40 -15.27 15.29 -23.65 -44.68 -53.72 -66.85 -40.89 -93.11

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds -67 108 139 100 32 158 185 296 -19
Non Curr. Liab. 7 6 9 10 10 10 12 7 56
Curr. Liab. 145 94 39 37 125 108 116 95 235
Minority Int.
Equity & Liab. 86 209 188 147 167 277 313 398 273
Non Curr. Assets 67 69 77 83 99 118 138 141 205
Curr. Assets 18 139 110 63 67 158 175 257 67
Misc. Exp. not W/O 0 1 1 0 1
Total Assets 86 209 188 147 167 277 313 398 273

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 29 87 167 156 161 181 78 183 77
Other Income 1 2 10 3 3 14 5 14 10
Total Income 30 89 177 159 164 195 83 196 87
Total Expenditure -99 -104 -134 -191 -224 -304 -321 -334 -387
PBIDT -69 -15 43 -32 -60 -109 -238 -138 -300
Interest 0 -4 -6 0 -2 -2 0 0 -3
Depreciation -3 -3 -4 -7 -8 -8 -8 -8 -9
Taxation -4
Exceptional Items 49
PAT -72 -22 30 -40 -70 -119 -197 -145 -312

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. -69 -95 37 -41 -44 -128 -183 -172 -211
Cash Fr. Inv. -2 -99 44 53 -13 -7 -105 -102 155
Cash Fr. Finan. 72 194 -81 -1 51 194 224 274 55
Net Change 0 0 0 11 -7 60 -63 0
Cash & Cash Eqvt 1 0 0 11 4 64 0 0 0

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 68.46 68.46 68.46 68.46 68.46 68.46 68.46 68.46 68.46
Public 31.54 31.54 31.54 31.54 31.54 31.54 31.54 31.54 31.54
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 3.05 3.05 3.05 1.32 1.90 1.90 0.75 2.29 2.29

Announcements View Details

Tue, 20 Jul 2021
Updates
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding 'Pursuant to Regulation 169(5) of the ICDR Regulations, please find enclosedherewith, a certificate issued by S R B C & Co LLP, Chartered Accountants, StatutoryAuditors of the Company, certifying that the issuer (i.e. Company) is in compliancewith Regulation 169(4) of ICDR Regulations and the relevant documents thereof aremaintained by the issuer as on the date of the certificate.'.
Thu, 15 Jul 2021
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Sun Pharma Advanced Research Company Limited has informed the Exchange about Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2021
Fri, 09 Jul 2021
Allotment of Securities
Sun Pharma Advanced Research Company Limited has informed the Exchange regarding allotment of 62474082 securities pursuant to Preferential Issue at its meeting held on July 08, 2021

Technical Scans View Details

Mon, 26 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index
Close Within 2 Year High Zone Close Within 2 Year High Zone
Both SRS And ARS Above Zero Both SRS And ARS Above Zero
Close Crossing Upper Bollinger Band From Above Close Crossing Upper Bollinger Band From Above

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Syngene International Ltd. 25,210.10 629.00 +0.2%
Quess Corp Ltd. 11,776.02 797.00 -0.3%
RattanIndia Enterprises Ltd. 9,302.67 67.30 +5.0%
SIS Ltd. 7,611.49 518.75 +5.4%
TeamLease Services Ltd. 6,854.09 4,009.00 +1.4%
Just Dial Ltd. 6,016.64 964.70 -0.5%
Delta Corp Ltd. 4,768.09 178.70 -0.4%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Syngene International Ltd. Consolidated 2021-06 59.43 629.00 +0.2%
Quess Corp Ltd. Consolidated 2021-03 203.47 797.00 -0.3%
RattanIndia Enterprises Ltd. Consolidated 2021-03 0.00 67.30 +5.0%
SIS Ltd. Consolidated 2021-03 20.83 518.75 +5.4%
TeamLease Services Ltd. Consolidated 2021-03 88.44 4,009.00 +1.4%
Just Dial Ltd. Consolidated 2021-06 47.26 964.70 -0.5%
Delta Corp Ltd. Consolidated 2021-06 0.00 178.70 -0.4%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Syngene International Ltd. Consolidated 2021-06 8.93 629.00 +0.2%
Quess Corp Ltd. Consolidated 2021-03 5.03 797.00 -0.3%
RattanIndia Enterprises Ltd. Consolidated 2021-03 109.64 67.30 +5.0%
SIS Ltd. Consolidated 2021-03 4.42 518.75 +5.4%
TeamLease Services Ltd. Consolidated 2021-03 10.52 4,009.00 +1.4%
Just Dial Ltd. Consolidated 2021-06 4.77 964.70 -0.5%
Delta Corp Ltd. Consolidated 2021-06 2.49 178.70 -0.4%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Syngene International Ltd. Consolidated 2021-03 0.28 629.00 +0.2%
Quess Corp Ltd. Consolidated 2020-03 0.51 797.00 -0.3%
RattanIndia Enterprises Ltd. Consolidated 2020-03 0.00 67.30 +5.0%
SIS Ltd. Consolidated 2021-03 0.74 518.75 +5.4%
TeamLease Services Ltd. Consolidated 2020-03 0.14 4,009.00 +1.4%
Just Dial Ltd. Consolidated 2020-03 0.00 964.70 -0.5%
Delta Corp Ltd. Consolidated 2020-03 0.00 178.70 -0.4%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Syngene International Ltd. Consolidated 2021-03 16.59 629.00 +0.2%
Quess Corp Ltd. Consolidated 2020-03 -16.80 797.00 -0.3%
RattanIndia Enterprises Ltd. Consolidated 2020-03 -0.24 67.30 +5.0%
SIS Ltd. Consolidated 2021-03 23.02 518.75 +5.4%
TeamLease Services Ltd. Consolidated 2020-03 6.75 4,009.00 +1.4%
Just Dial Ltd. Consolidated 2020-03 24.85 964.70 -0.5%
Delta Corp Ltd. Consolidated 2020-03 9.59 178.70 -0.4%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Syngene International Ltd. Consolidated 2021-03 15.40 629.00 +0.2%
Quess Corp Ltd. Consolidated 2020-03 -5.79 797.00 -0.3%
RattanIndia Enterprises Ltd. Consolidated 2020-03 0.63 67.30 +5.0%
SIS Ltd. Consolidated 2021-03 21.05 518.75 +5.4%
TeamLease Services Ltd. Consolidated 2020-03 16.25 4,009.00 +1.4%
Just Dial Ltd. Consolidated 2020-03 31.48 964.70 -0.5%
Delta Corp Ltd. Consolidated 2020-03 13.98 178.70 -0.4%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Syngene International Ltd. Consolidated 2021-03 2,184.30 629.00 +0.2%
Quess Corp Ltd. Consolidated 2020-03 10,991.48 797.00 -0.3%
RattanIndia Enterprises Ltd. Consolidated 2020-03 67.30 +5.0%
SIS Ltd. Consolidated 2021-03 9,127.30 518.75 +5.4%
TeamLease Services Ltd. Consolidated 2020-03 5,200.72 4,009.00 +1.4%
Just Dial Ltd. Consolidated 2020-03 953.11 964.70 -0.5%
Delta Corp Ltd. Consolidated 2020-03 773.41 178.70 -0.4%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Syngene International Ltd. Consolidated 2021-03 404.90 629.00 +0.2%
Quess Corp Ltd. Consolidated 2020-03 -418.05 797.00 -0.3%
RattanIndia Enterprises Ltd. Consolidated 2020-03 -0.38 67.30 +5.0%
SIS Ltd. Consolidated 2021-03 366.66 518.75 +5.4%
TeamLease Services Ltd. Consolidated 2020-03 37.06 4,009.00 +1.4%
Just Dial Ltd. Consolidated 2020-03 272.31 964.70 -0.5%
Delta Corp Ltd. Consolidated 2020-03 184.78 178.70 -0.4%